Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2294 | Matched placebo Wiki | 1.00 |
| drug1186 | Descartes 30 Wiki | 1.00 |
| drug4752 | standard prophylactic dose Enoxaparin/ unfractionated heparin Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
In a 2x2 factorial design randomized controlled trial, the investigators aim to elaborate the safety and efficacy of two pharmacological regimens on outcomes of critically-ill patients with COVID-19. The first randomization entails open-label assignment to intermediate versus standard dose prophylactic anticoagulation. The investigators hypothesize that intermediate dose compared with standard prophylactic dose anticoagulation will have a superior efficacy with respect to a composite of venous thromboembolism (VTE), requirement for extracorporeal membrane oxygenation (ECMO), or all-cause mortality. The second randomization will be double-blind assignment of the included patients to atorvastatin 20mg daily versus matching placebo. The hypothesis is that statin therapy, compared with placebo, will reduce the composite of VTE, need for ECMO, or all-cause mortality.
Description: Composite of objectively-confirmed venous thromboembolism, undergoing extracorporeal membrane oxygenation (ECMO), or death from any cause
Measure: Composite of incident VTE, undergoing ECMO, and all-cause mortality Time: 30 days from enrollmentDescription: Patient status regarding to being alive or dead at the end of 30-day follow up
Measure: Rate of all-cause mortality Time: 30 days from enrollmentDescription: Distal or proximal deep vein thrombosis which has been confirmed by ultrasonography or venography/ PE confirmed by at least one CTPA or lung scan
Measure: Rate of objectively-confirmed VTE Time: 30 days from enrollmentDescription: Difference between days of ICU stay and days on invasive mechanical ventilation
Measure: Ventilator free days Time: 30 days from enrollmentDescription: According to the Bleeding Academic Research Consortium (BARC 3 or 5 bleeding)
Measure: Rate of major bleeding Time: 30 days from enrollmentDescription: Clinically-significant bleeding, not fulfilling criteria for major bleeding)
Measure: Rate of clinically-relevant non-major bleeding Time: 30 days from enrollmentDescription: Platelet count <20.000
Measure: Rate of severe thrombocytopenia Time: 30 days from enrollmentDescription: Increase liver function tests>3 times
Measure: Rate of rise in liver enzymes Time: 30 days from enrollmentDescription: According to the fourth universal definition of myocardial infraction and confirmed by coronary angiography, intravascular imaging or autopsy
Measure: Rate of objectively clinically-diagnosed type I acute myocardial infarction Time: 30 days from enrollmentDescription: Any stroke episode which has been confirmed with appropriate diagnostic imaging (brain CT and/or brain MRI)
Measure: Rate of objectively clinically -diagnosed stroke Time: 30 days from enrollmentDescription: Imaging confirmed acute peripheral arterial thrombosis (by ultrasonography, CT, MRI, or invasive angiography)
Measure: Rate of objectively clinically -diagnosed acute peripheral arterial thrombosis Time: 30 days from enrollmentDescription: Number of days that a patient has stayed in the ICU
Measure: Median ICU length of stay Time: 30 days from enrollmentDescription: Status of patients regarding to mortality (alive/dead) at the time of discharge from ICU
Measure: ICU discharge status Time: 30 days from enrollmentDescription: Any AF episode which has been confirmed by at least one ECG or telemetry monitoring, in patients without prior history of AF
Measure: Incident atrial fibrillation Time: 30 days from enrollmentDescription: Use hemodialysis or veno-venous hemofiltration or peritoneal dialysis for a patient during the hospitalization period, due to acute kidney injury
Measure: Rate of need for renal replacement therapy Time: 30 days from enrollmentDescription: Based on Post-COVID-19 Functional Status questionnaire, which varies fro score 0 to 4, and higher scores mean worse outcome.
Measure: Post-COVID-19 Functional Status Time: 60 and 90 -dayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports